Rheumatoid Arthritis Clinical Trials Near You

Rheumatoid arthritis (RA) research is pushing beyond current biologics and JAK inhibitors toward more fundamental disease modification. CAR-T cell therapy, adapted from cancer treatment, is entering RA trials — Phase 1–2 studies are testing CD19-targeted CAR-T cells that deplete the B lymphocytes driving RA autoimmunity more completely and durably than rituximab. Dramatic remissions seen in lupus CAR-T trials have accelerated RA-specific programs.

Biologic tapering and drug-free remission studies are examining whether patients in sustained remission can safely reduce or discontinue medications without disease flares. These treat-to-target withdrawal trials identify the minimum effective dose, reducing costs, infection risks, and long-term side effects.

Prevention trials represent a paradigm shift: researchers are testing whether hydroxychloroquine, abatacept, or other interventions can prevent RA from developing in at-risk individuals — people with anti-CCP antibodies and joint pain but no clinical arthritis yet.

JAK inhibitors (tofacitinib, baricitinib, upadacitinib) continue to be refined, with trials studying which patient profiles respond best to oral JAK inhibitors versus injectable biologics. Post-marketing safety studies address cardiovascular and thromboembolism signals from earlier trials.

Patient considerations: RA trials typically require documented failure of at least one conventional DMARD (usually methotrexate for 3+ months). Expect regular joint assessments (DAS28, ACR criteria), blood tests for inflammatory markers (CRP, ESR) and liver function, and possibly imaging of hands and feet. Many trials allow continued methotrexate alongside the study drug.